ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Gao, Xin; Wei, Xue-Wu; Zheng, Ming-Ying; Chen, Zhi-Hong; Zhang, Xu-Chao; Zhong, Wen-Zhao; Yang, Jin-Ji; Wu, Yi-Long; Zhou, Qing*广东省人民医院; 南方医科大学
Journal of Thoracic Disease2020-10DOI: 10.21037/jtd-20-1630
3被引10阅读
引用收藏
分享

摘要

Background: Epidermal growth factor receptor (EGFR) exon 20 insertion (EGFR ex20ins) is a common mutation in non-small cell lung cancer (NSCLC). Patients with EGFR ex20ins generally respond poor to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). EGFR ex20ins are often co-occurring with EGFR amplification. However, the impact of EGFR amplification on the survival of patients with EGFR ex20ins mutations has not been determined. @@@ Methods: This is an observational longitudinal cohort study. A prospectively managed database included consecutive treatment-naive adult patients with advanced NSCLC and EGFR ex20ins confirmed by next-generation sequencing (NGS) at Guangdong Provincial Peoples Hospital between November 2017 and February 2019. The participants were enrolled from the database and extracted their clinical characteristics, treatment and clinical outcomes. NGS was used to establish whether EGFR amplification was present in tumor tissue. Overall survival (OS) and progression-free survival (PFS) were compared between EGFR amplification and non-EGFR amplification groups using the Kaplan-Meier method and log-rank test. Subgroup analyses were performed based on the treatment used (EGFR-TKI or chemotherapy). @@@ Results: Fifteen different EGFR ex20ins mutation subtypes were identified in the 39 patients included in the analysis, and the most common subtypes were p.A767_D770dup (25.6%), p.S768_D770dup (23.1%) and p.N771_H773dup (10.3%). Among 31 patients with EGFR ex20ins mutations and NGS data for tumor tissue, EGFR amplification was identified in 12 patients (38.7%) and there were no significant differences in clinical characteristics. Among 26 patients, there were no significant differences between the EGFR amplification (n=11) and non-EGFR amplification (n=15) groups in median OS (715 vs. 452 days, P=0.912). Among 20 patients administered chemotherapy, there were no significant differences between the EGFR amplification and non-EGFR amplification groups in median PFS (206 vs. 112 days, P=0.425). Among 24 patients administered an EGFR-TKI, median PFS was longer in the non-EGFR amplification group than in the EGFR amplification group (110 vs. 31 days, P=0.030). @@@ Conclusions: There is a tendency that EGFR amplification might be a poor predictor in EGFR ex20ins-positive NSCLC patients treated with EGFR-TKIs.

学科与关键词

关键词
Non-small cell lung cancer (NSCLC)epidermal growth factor receptorexon 20gene insertiongene amplification
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Thoracic Disease
发表日期
2020-10
卷期
第 12 卷, 第 10 期
页码
5822-+
DOI
10.21037/jtd-20-1630
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
4区
成果收录
SCIE
资助标注
National Key R&D Program of China [2016YFC1303800]; National Natural Science Foundation of China [81871891]; High-level Hospital Construction Project [DFJH201810]; Key Lab System Project of Guangdong Science and Technology Department-Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]

作者

  • G

    Gao, Xin (第一作者)

    2 · southern med univ

  • W

    Wei, Xue-Wu

查看全部 9 位作者收起作者
  • Z

    Zheng, Ming-Ying

  • C

    Chen, Zhi-Hong

  • Z

    Zhang, Xu-Chao

  • Z

    Zhong, Wen-Zhao

  • Y

    Yang, Jin-Ji

  • W

    Wu, Yi-Long

  • Z

    Zhou, Qing (通讯)

    2 · guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417